COAG
Hemab Therapeutics Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsLast reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Hemab Therapeutics Holdings, Inc.
Expected move
InputsLast reportshaded = implied▲▼ = realized× = |realized| ÷ implied
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $286.8M | 21.58% | new | |
| 2 | NovoNovo | $153.6M | 11.55% | new | |
| 3 | FMRFMR | $135.8M | 10.22% | new | |
| 4 | Capital International InvestorsCapital International Investors | $132.4M | 9.96% | new | |
| 5 | Deep Track CapitalDeep Track Capital | $132.3M | 9.96% | new | |
| 6 | SirenSiren | $76.6M | 5.77% | new | |
| 7 | venBio Select AdvisorvenBio Select Advisor | $70.7M | 5.32% | new | |
| 8 | Bain Capital Life Sciences InvestorsBain Capital Life Sciences Investors | $60.6M | 4.56% | new | |
| 9 | JPMorgan ChaseJPMorgan Chase | $42.3M | 3.18% | new | |
| 10 | Vanguard Capital ManagementVanguardindex-like | $28.7M | 2.16% | new | |
| 11 | T. Rowe Price AssociatesT. Rowe Price | $27.4M | 2.06% | new | |
| 12 | Driehaus Capital ManagementDriehaus | $26.3M | 1.98% | new | |
| 13 | Rock Springs Capital ManagementRock Springs | $21.1M | 1.59% | new | |
| 14 | Bellevue GroupBellevue | $20.2M | 1.52% | new | |
| 15 | Citadel AdvisorsCitadel | $19.2M | 1.45% | new | |
| 16 | BlackRockBlackRockindex-like | $10.4M | 0.78% | new | |
| 17 | Deerfield ManagementDeerfield | $10.1M | 0.76% | new | |
| 18 | ExodusPoint Capital ManagementExodusPoint | $8.0M | 0.60% | new | |
| 19 | Geode Capital ManagementGeodeindex-like | $7.8M | 0.59% | new | |
| 20 | BraidwellBraidwell | $5.9M | 0.44% | new | |
| 21 | Marshall WaceMarshall Wace | $5.7M | 0.43% | new | |
| 22 | Woodline PartnersWoodline Partners | $5.5M | 0.41% | new | |
| 23 | Affinity Asset AdvisorsAffinity Asset | $5.1M | 0.38% | new | |
| 24 | Ensign Peak AdvisorsEnsign Peak | $4.2M | 0.32% | new | |
| 25 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $4.1M | 0.31% | new |
No thesis.
Hemab Therapeutics Holdings, Inc.
41.49
54 managers report $1.3B of Hemab Therapeutics on form 13F for the quarter ended Jun 30 '26. 9 of them hold 80% of it; RA Capital Management is largest at 21.58%.
Linked news
Expected move
No implied move.
No implied move.
No implied move.